256
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

Synthesis of Substituted Aryl Incorporated Oxazolo[4,5-b]Pyridine-Triazole Derivatives: Anticancer Evaluation and Molecular Docking Studies

, , , , &
Pages 915-932 | Received 24 Jul 2021, Accepted 08 Dec 2021, Published online: 27 Dec 2021
 

Abstract

A new series of structurally modified oxazolo[4,5-b]pyridine based triazoles (18a–j) derivatives were synthesized, and designed and screened for their anticancer activities against human cancer cell lines like PC3 (prostate), A549 (lung), MCF-7 (breast), and DU-145 (prostate) by using MTT assay method. Most of the tested compounds exhibited good to moderate anticancer potential in comparison with etoposide. Among all, compounds 18a, 18b, 18c, 18d, 18e, and 18i displayed promising anticancer activities on four cell lines. Furthermore, molecular docking studies were carried out on human dihydroorotate dehydrogenase (hDHODH), a potential target for anticancer drugs, that is linked to proliferation, invasion, and migration of cancerous cell in acute myeloid leukemia, colorectal cancer melanoma, and pancreatic cancer cells. The investigated oxazolo[4,5-b]pyridine-based triazoles (18a–j) showed efficient inhibition of hDHODH in molecular docking studies.

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.